Pharmacology
Every board exam has 8-12 antibiotic questions. Mechanisms, coverage, side effects, and the traps they set. This is the single highest-yield pharm topic you'll see.
Every antibiotic does one of five things. Know the mechanism, and coverage and side effects follow logically.
Beta-lactams bind PBPs. Vancomycin binds D-ala-D-ala directly (different target, same wall).
Aminoglycosides and Tetracyclines = "AT 30." Aminoglycosides cause misreading (bactericidal). Tetracyclines block tRNA attachment (bacteriostatic).
"Buy AT 30, CELL at 50" — Chloramphenicol, Erythromycin (macrolides), Linezolid, cLindamycin. 🔑 Buy AT 30, CELL at 50 — Aminoglycosides & Tetracyclines at 30S. Chloramphenicol, Erythromycin, Linezolid, cLindamycin at 50S.
FQs block gyrase (gram-neg) and topo IV (gram-pos). Metronidazole forms toxic free radicals that shred DNA. Rifampin blocks RNA polymerase.
Double blockade: sulfamethoxazoleSulfa drugs are structural analogs of PABA — they competitively inhibit dihydropteroate synthase, the first step in bacterial folate synthesis. Humans don't have this enzyme (we get folate from food), so sulfa drugs are selectively toxic to bacteria. blocks step 1, trimethoprimTrimethoprim inhibits dihydrofolate reductase (DHFR) — the second step in folate synthesis. Bacterial DHFR and human DHFR are structurally different, giving selectivity. But high doses or long courses can still cause folate deficiency in humans → megaloblastic anemia. blocks step 2. Synergistic — two hits on the same pathway.
Drag each antibiotic to its mechanism. This is how boards test it — they give you the drug name and expect you to know the target.
This is the table that lives in your head on test day. Boards give you an infection and expect you to pick the right drug. Know who covers what.
| Drug Class | Gram+ | Gram− | Anaerobes | Pseudomonas | MRSA | Atypicals |
|---|---|---|---|---|---|---|
| Penicillin G/V | +++ | − | + | − | − | − |
| Ampicillin/Amoxicillin | +++ | + | + | − | − | − |
| Pip/Tazo (Zosyn) | +++ | +++ | +++ | ✓ | − | − |
| Cefazolin (1st gen) | +++ | + | − | − | − | − |
| Ceftriaxone (3rd gen) | + | +++ | − | − | − | − |
| Cefepime (4th gen) | ++ | +++ | − | ✓ | − | − |
| Carbapenems | +++ | +++ | +++ | ✓ | − | − |
| Azithromycin | + | + | − | − | − | ✓ |
| Fluoroquinolones | ++ | +++ | − | ✓ | − | ✓ |
| Vancomycin | +++ | − | − | − | ✓ | − |
| TMP-SMX | ++ | ++ | − | − | ✓ | − |
| Metronidazole | − | − | +++ | − | − | − |
| Doxycycline | + | + | − | − | + | ✓ |
| Linezolid | +++ | − | − | − | ✓ | − |
The pattern is simple: as generations go up, gram-negative coverage increases and gram-positive coverage decreases. Except 4th gen, which gets both back.
| Gen | Example | Gram+ | Gram− | Special | Board Use |
|---|---|---|---|---|---|
| 1st | Cefazolin, Cephalexin | +++ | + | — | Surgical prophylaxis, skin infections |
| 2nd | Cefoxitin, Cefuroxime | ++ | ++ | Cefoxitin: anaerobes | Mixed infections, aspiration PNA |
| 3rd | Ceftriaxone, Ceftazidime | + | +++ | Crosses BBB. Ceftazidime: Pseudomonas | Meningitis, gonorrhea, serious GNR |
| 4th | Cefepime | ++ | +++ | Pseudomonas + expanded | Febrile neutropenia, nosocomial |
| 5th | Ceftaroline | +++ | ++ | MRSA coverage | The ONLY beta-lactam that covers MRSA |
Side effects are half of antibiotic questions. They describe a clinical scenario and expect you to name the drug. These are the ones that always show up.
A patient walks in. Four drugs are options. Clinical clues eliminate one at a time until only the answer remains.
Patient has an infection. Pick the drug. This is how it shows up on test day.
Monotherapy is fine. Azithromycin used to be first-line but S. pneumoniae resistance rates are too high now. If the question gives azithromycin as the only option for healthy outpatient CAP, it might still be "correct" on older exams.
Need to cover atypicals (Mycoplasma, Legionella) plus typical bacteria. Respiratory FQ = levofloxacin or moxifloxacin (NOT cipro — cipro has poor pneumococcal coverage).
Ceftriaxone covers S. pneumoniae and gram-negatives. Azithromycin adds atypical coverage. This is the most-tested empiric regimen for inpatient CAP.
Ampicillin covers Listeria and GBS. Cefotaxime covers E. coli. NOT ceftriaxone in neonates — displaces bilirubin from albumin → kernicterus risk.
Ceftriaxone for S. pneumoniae and N. meningitidis. Vancomycin for resistant pneumococcus. Dexamethasone BEFORE or WITH first antibiotic dose — reduces inflammation and improves outcomes. Give steroids late = no benefit.
Add ampicillin for Listeria. Listeria is the bug boards love for elderly and immunocompromised meningitis. Cephalosporins do NOT cover Listeria.
Incision and drainage is the #1 intervention for abscess. Oral antibiotics are adjunctive. TMP-SMX and doxycycline both have community MRSA coverage.
Daptomycin is inactivated by surfactant — never use for pneumonia. If the question says MRSA pneumonia, the answer is vancomycin (or linezolid). Daptomycin for bloodstream/skin only.
First-line. Avoid FQs for simple UTI — save them for complicated infections. Nitrofurantoin only works in the bladder (concentrates in urine, no systemic levels).
TMP-SMX is teratogenic in 1st trimester (folate antagonist) and causes kernicterus near term. FQs and tetracyclines are contraindicated. Nitrofurantoin is safe but avoid near term (hemolysis in G6PD-deficient neonates).
Monotherapy with a broad-spectrum agent. All cover Pseudomonas. Pick based on local antibiogram.
Triple therapy: pip/tazo or meropenem (beta-lactam) + cipro or tobramycin (double Pseudomonas coverage) + vancomycin or linezolid (MRSA). Two anti-pseudomonal agents from different classes = double coverage.
5 patients. 5 antibiotics questions. Board-style vignettes. Don't prescribe anything that'll hurt them.